Sanofi agreed to acquire Dynavax Technologies for about $2.2 billion in cash, adding the commercial hepatitis B vaccine Heplisav‑B and a Phase I/II shingles candidate to its vaccine lineup. The deal, reported by MedCity News, gives Sanofi immediate commercial revenue and an advancing shingles program that could differentiate against GSK incumbents. This is Sanofi’s second billion‑dollar vaccine acquisition in 2025 and will reshape its near‑term vaccine portfolio and R&D priorities.